BMC aims to provide New England with a state-of-the-art tertiary care center for oral and oral pharyngeal cancers. The patient-centered, multidisciplinary approach assures each patient benefits from the collaborative expertise of physicians uniquely focused on their individual needs.
BMC’s Director of Maxillofacial Oncology, Andrew Salama, DDS, MD, is a dually-qualified oral and maxillofacial surgeon who brings a unique dentally-minded perspective to his patient care. Dr. Salama is leading his team to provide the latest technologies and practices in oral and pharyngeal cancer treatment. His current clinical research involves evaluating tongue motion and speech following reconstructive surgery and developing novel chemo-preventive medications for oral cancer.